-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

984 Romidepsin, Azacitidine, Dexamethasone, and Lenalidomide (RAdR) for Relapsed/Refractory T-Cell Lymphoma

Program: Oral and Poster Abstracts
Type: Oral
Session: 625. T Cell, NK Cell, or NK/T Cell Lymphomas: Clinical and Epidemiological: Are We Ready to Move the Needle in T Cell Lymphomas?
Hematology Disease Topics & Pathways:
Research, Clinical trials, Combination therapy, Lymphomas, Clinical Research, T Cell lymphoma, Diseases, Treatment Considerations, Lymphoid Malignancies
Monday, December 9, 2024: 5:45 PM

Max J Gordon, MD1*, Milos D Miljkovic, MD, MSc2, Samuel Ng, MD, PhD3, Rahul Lakhotia, MBBS1, Christopher Melani, MD4, Kevin Conlon3*, James D. Phelan, PhD1*, Bonita Bryant1*, Laura M Yee5*, Stefania Pittaluga, MD, PhD6*, Elaine S. Jaffe, MD7, Louis M. Staudt, MD, PhD8, Wyndham H. Wilson, MD, PhD1* and Mark Roschewski, MD3

1Lymphoid Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD
2Cartesian Therapeutics, Inc., Washington, DC
3National Cancer Institute, Bethesda, MD
4Lymphoid Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Derwood, MD
5Office of Collaborative Biostatistics, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD
6Laboratory of Pathology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD
7Laboratory of Pathology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Great Falls, VA
8Metabolism Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD

Mature T-cell lymphomas (TCL) are a heterogeneous group of diseases with a poor prognosis, particularly in the relapsed/refractory (r/r) setting. Drugs targeting epigenetic regulation and immunomodulation such as romidepsin, azacitidine and lenalidomide have single agent activity against r/r TCL with objective response rates (ORR) and complete response rates (CR) around 30% and 10%. Lenalidomide and romidepsin have each been combined with azacitidine showing improved rates of CR, but extended treatment schedules add toxicity. We hypothesized that cyclic, time-limited administration of a multi-targeted combination regimen would induce durable remissions.

We tested escalating doses of lenalidomide (5 to 20mg) with fixed doses of romidepsin, azacitidine and dexamethasone. Eligible patients were ≥18 years old with r/r TCL and had received at least 1 prior line of therapy (must have included brentuximab vedotin if anaplastic large cell lymphoma [ALCL] or CD30+ mycosis fungoides [MF]). Prior allogeneic transplantation was allowed. Patients first received a 7-day course of lenalidomide for correlative research followed by up to six 28-day cycles of romidepsin (12mg/m2; days 1 and 10), azacitidine (300mg; days 1-10), dexamethasone (40mg; days 1 and 10), and lenalidomide (5-20mg; days 1-10) without maintenance. The primary objective was to test the overall safety of the regimen and the primary endpoint was the maximum tolerated dose (MTD) of lenalidomide. A 3+3 design was used with an additional 9 patients treated at the MTD. Survival was estimated using the Kaplan-Meier method; patients were censored at time of allogeneic transplantation (SCT). The study was supported by the Intramural Research Program of the NIH and was registered at Clinicaltrials.gov (NCT04447027).

Twenty-six patients with r/r TCL were enrolled during 2020-2024. The median age was 61 years (range, 28-80) and 23% were ≥70 years old. Eighteen (69%) were male, 42% were black, 31% white, 15% Asian and 12% Hispanic. Nodal TCL subtypes were the most common (62%) including peripheral T-cell lymphoma not otherwise specified (31%; PTCL, NOS) and angioimmunoblastic (19%). Six (23%) had MF and four (15%) had adult T-cell leukemia/lymphoma. Median prior lines of therapy were 2 (range, 1-8), 31% had received ≥4 prior lines and 2 patients had received prior SCT.

Two dose-limiting toxicities were observed, grade 4 thrombocytopenia at dose level 1 and grade 3 abdominal pain at dose level 2; the MTD of lenalidomide was determined to be 20mg. Grade ≥3 non-hematologic adverse events (AE) included hypokalemia (12%), kidney injury, adrenal insufficiency, fatigue, anorexia, weight loss and infection (all, 8%). Grade ≥3 neutropenia, thrombocytopenia and anemia occurred in 17%, 15% and 13% of cycles.

The median number of cycles were 4 (range, 1-6), eight (31%) completed the planned 6 cycles of treatment. Ten (38%) discontinued for progression, 23% due to toxicity (four due to thrombocytopenia, one each due to abdominal pain and anxiety) and 8% due to patient/provider preference. Seven (27%) patients required dose reduction.

One patient withdrew during the lenalidomide lead-in and was not included in the efficacy analyses. In patients who received RAdR (N=25) the ORR was 56%, 95% CI (34.9% - 75.6%) and CR 12%, 95% CI (2.5% - 31.2%). After a median follow up of 18.2 months, 1-year progression-free survival (PFS) was 14.9%, 95% CI (5.4% - 41.1%) and 1-year overall survival (OS) was 63.3%, 95% CI (45.8% - 87.4%). Two patients (PTCL, NOS and MF) remain in remission off therapy after more than 36 months of follow up without consolidation. All 5 patients who received consolidative SCT are alive at 19-39 months of follow up.

In patients with nodal TCL (N=16) the ORR was 63%, 95% CI (35.4% - 84.8%) and CR 19%, 95% CI (4.0% - 45.6%). 1-year PFS was 16.9%, 95% CI (5.0% - 57.4%) and 1-year OS was 70.3%, 95% CI (49.5% - 99.8%). In patients treated at the MTD (N=9: 5 PTCL, NOS, 2 ALCL, ALK- and 2 MF) the ORR was 89%, 95% CI (51.8% - 99.7%) and CR 22%, 95% CI (2.8% - 60.0%). 1-year PFS was 11.1%, 95% CI (1.8% - 70.5%) and 1-year OS was 71.4%, 95% CI (44.7% - 100%).

Multiagent targeted therapy with RAdR is safe in r/r TCL and induces a high rate of response, particularly at the MTD, but durable complete responses are uncommon without consolidation. The four-drug regimen is active across the diverse spectrum of TCL subtypes and may be an effective therapeutic bridge to transplantation.

Disclosures: Miljkovic: Cartesian Therapeutics: Current Employment, Current equity holder in publicly-traded company.

OffLabel Disclosure: Romidepsin, azacitidine and lenalidomide were tested in combination in patients with relapsed or refractory T-cell malignancies.

<< Previous Abstract | Next Abstract
*signifies non-member of ASH